Feedback Reports on Collaboration with Princess Alexandra Hospital, AU
The study will be led by Prof. Ken Miles (Senior Medical Officer in the Diagnostic Radiology department of PAH). Prof. Miles is also a Professorial Research Associate in the Institute of Nuclear Medicine, University College London, UK. Prof. Miles has an international reputation in functional imaging of tumours, ranging from the development of new techniques through to demonstrating cost-effectiveness. For example he has been one of the pioneers of CT perfusion (blood-flow) and CT texture (heterogeneity) analysis technologies.
Prof. Ken Miles commented:
"TexRAD as research software has been used to investigate lung cancer on CT where it has been shown to be associated with underlying tumour biology and has the potential to be an independent prognostic marker. Preliminary studies have also demonstrated potential clinical applications for TexRAD analysis to assist treatment decisions and optimise lung cancer patient management in a cost-effective manner. We hope this study will demonstrate that TexRAD could be incorporated into the routine radiological workflow."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:
"Prof. Ken Miles is one of the top functional imaging academics, dual trained in radiology and nuclear medicine and we are delighted that he will be leading the very first landmark study in evaluating potential clinical implementation with our TexRAD software focused on lung cancer. Working with Princess Alexandra Hospital in Brisbane will enhance our TexRAD research collaborator base with the addition of a key site in this new geographical region."
Комментарии